Patents by Inventor Lenka Van Sint Fiet
Lenka Van Sint Fiet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132890Abstract: The invention relates to nucleic acid molecules for pseudouridylation of a target uridine in a target RNA in a mammalian cell, wherein the nucleic acid molecule comprises a guide region capable of forming a partially double stranded nucleic acid complex with the target RNA comprising the target uridine, wherein the partially double stranded nucleic acid complex is capable of engaging a mammalian pseudouridylation enzyme, wherein the guide region assists in positioning the target uridine in the partially double stranded nucleic acid complex for it to be converted to a pseudouridine by the mammalian pseudouridylation enzyme.Type: ApplicationFiled: September 27, 2023Publication date: April 25, 2024Applicants: University of Rochester, ProQR Therapeutics II B.V.Inventors: Bart KLEIN, Janne Juha TURUNEN, Lenka VAN SINT FIET, Pedro Duarte Morais Fernandes Arantes DA SILVA, Julien Auguste Germain BOUDET, Yi-Tao YU, Hironori ADACHI, Meemanage De ZOYSA
-
Patent number: 11866702Abstract: The invention relates to nucleic acid molecules for pseudouridylation of a target uridine in a target RNA in a mammalian cell, wherein the nucleic acid molecule comprises a guide region capable of forming a partially double stranded nucleic acid complex with the target RNA comprising the target uridine, wherein the partially double stranded nucleic acid complex is capable of engaging a mammalian pseudouridylation enzyme, wherein the guide region assists in positioning the target uridine in the partially double stranded nucleic acid complex for it to be converted to a pseudouridine by the mammalian pseudouridylation enzyme.Type: GrantFiled: March 27, 2019Date of Patent: January 9, 2024Assignees: University of Rochester, ProQR Therapeutics II B.V.Inventors: Bart Klein, Janne Juha Turunen, Lenka Van Sint Fiet, Pedro Duarte Morais Fernandes Arantes Da Silva, Julien Auguste Germain Boudet, Yi-Tao Yu, Hironori Adachi, Meemanage De Zoysa
-
Patent number: 11851656Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.Type: GrantFiled: January 20, 2021Date of Patent: December 26, 2023Assignee: ProQR Therapeutics II B.V.Inventors: Janne Juha Turunen, Antti Aalto, Bart Klein, Lenka Van Sint Fiet, Julien Auguste Germain Boudet
-
Publication number: 20230323346Abstract: The invention relates to a composition comprising a set of two single stranded antisense oligonucleotides (AONs), wherein one AON is the ‘Editing AON’ and the other AON is the ‘Helper AON’, for use in the deamination of a target adenosine in a target RNA to an inosine, wherein the Editing AON is complementary to a stretch of nucleotides in the target RNA that includes the target adenosine, wherein the Helper AON is complementary to a stretch of nucleotides in the target RNA that is separate from the stretch of nucleotides that is complementary to the Editing AON, wherein the Helper AON has a length of 16 to 22 nucleotides and the Editing AON has a length of 16 to 22 nucleotides.Type: ApplicationFiled: July 22, 2021Publication date: October 12, 2023Inventors: Lenka VAN SINT FIET, Alicia SOLER CANTÓN
-
Publication number: 20230279392Abstract: The invention relates to antisense oligonucleotide that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine (a non-complementary nucleotide) or a uridine in a position opposite to the target adenosine to be edited in the target RNA region.Type: ApplicationFiled: April 6, 2023Publication date: September 7, 2023Applicant: ProQR Therapeutics II B.V.Inventors: Janne Juha TURUNEN, Petra Geziena DE BRUIJN, Bart KLEIN, Roxana Simona REDIS, Lenka VAN SINT FIET
-
Publication number: 20230235322Abstract: An antisense oligonucleotide (AON) capable of inhibiting ADAR-mediated deamination of a target adenosine present in an editing-site sequence (ESS) of a target RNA molecule, wherein under physiological conditions the ESS would hybridize with an editing-site complementary sequence (ESCS) of an RNA molecule to form a double stranded RNA complex, wherein the AON comprises a sequence configured to compete with the ESCS for hybridization with the ESS.Type: ApplicationFiled: April 9, 2020Publication date: July 27, 2023Inventors: Janne Juha Turunen, Lenka Van Sint Fiet, Lisanne Alieda Van Wissen
-
Patent number: 11649454Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine (a non-complementary nucleotide) or a uridine in a position opposite to the target adenosine to be edited in the target RNA region.Type: GrantFiled: March 26, 2021Date of Patent: May 16, 2023Assignee: ProQR Therapeutics II B.V.Inventors: Janne Juha Turunen, Petra Geziena De Bruijn, Bart Klein, Roxana Simona Redis, Lenka Van Sint Fiet
-
Publication number: 20230039928Abstract: The invention relates to RNA editing oligonucleotides (EONs) that can bring about specific editing of a target nucleotide (adenosine) in a target RNA molecule in a eukaryotic cell, wherein said oligonucleotide is for use in the treatment of Stargardt disease, and more preferably for the deamination of target adenosines present in the ABCA4 pre-mRNA or ABCA4 mRNA.Type: ApplicationFiled: December 23, 2020Publication date: February 9, 2023Inventors: Jim Swildens, Lenka Van Sint Fiet, Tess Hoogeboom, Saskia Jacoba Petronella Haast
-
Publication number: 20220340900Abstract: The invention relates to single-stranded RNA editing antisense oligonucleotides (AONs) for binding to a target RNA molecule for deaminating a target nucleotide, preferably an adenosine, present in the target RNA molecule and recruiting, in a cell, preferably a human cell, an enzyme with nucleotide deamination activity, preferably an ADAR enzyme, to deaminate the target nucleotide in the target RNA molecule. The AONs carry at least one methylphosphonate-modified internucleosidic linkage on a position that would render the AON more stable in comparison to an AON not carrying that methylphosphonate modification at that position.Type: ApplicationFiled: April 2, 2020Publication date: October 27, 2022Inventors: Janne Juha Turunen, Bart Klein, Lenka Van Sint Fiet, Antti Aalto, Cherie Paige Kemmel, Tess Hoogeboom, Lisanne Alieda Van Wissen
-
Publication number: 20220307023Abstract: The invention relates to single-stranded RNA editing antisense oligonucleotides (AO Ns) for binding to a target RNA molecule for deaminating at least one target adenosine present in the target RNA molecule and recruiting, in a cell, preferably a human cell, an ADAR2 enzyme, to deaminate the at least one target adenosine in the target RNA molecule. The AON according to the invention comprises a cytidine analog at the position opposite the target adenosine, wherein the cytidine analog serves as an H-bond donor at the N3 site, for more efficient RNA editing.Type: ApplicationFiled: June 12, 2020Publication date: September 29, 2022Inventors: Janne Juha Turunen, Lenka Van Sint Fiet, Cherie Paige Kemmel, Peter Beal, Erin E. Doherty
-
Publication number: 20220127609Abstract: The invention relates to editing oligonucleotides (EONs) for binding to a target nucleic acid and recruiting an enzyme with nucleotide deamination activity to edit the target nucleic acid. The EONs carry phosphonoacetate internucleotide linkage modifications and/or unlocked nucleic acid (UNA) ribose modifications at specified positions and do not carry such modifications on positions that would lower nucleic acid editing efficiency. The selection of positions that should or should not carry a modification is based on computational modelling that revealed incompatibilities of the modifications with the enzyme with nucleotide deamination activity.Type: ApplicationFiled: February 10, 2020Publication date: April 28, 2022Inventors: Julien Auguste Germain Boudet, Lenka Van Sint Fiet
-
Publication number: 20220112495Abstract: The invention relates to RNA editing oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA molecule in a eukaryotic cell, wherein said oligonucleotide is for use in the treatment of Usher syndrome, and more preferably for the deamination of target adenosines that are part of a premature stop codon present in the USH2A pre-mRNA or USH2A mRNA.Type: ApplicationFiled: January 27, 2020Publication date: April 14, 2022Inventors: Lenka Van Sint Fiet, Kalyana Chakravarthi Dulla, Jim Swildens
-
Publication number: 20210340529Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine non-complementary, nucleotide) or a uridine in a position opposite to the target adenosine to be edited in the target RNA region.Type: ApplicationFiled: March 26, 2021Publication date: November 4, 2021Inventors: Janne Juha Turunen, Petra Geziena De Bruijn, Bart Klein, Roxana Simona Redis, Lenka Van Sint Fiet
-
Publication number: 20210238597Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.Type: ApplicationFiled: January 20, 2021Publication date: August 5, 2021Inventors: Janne Juha Turunen, Antti Aalto, Bart Klein, Lenka Van Sint Fiet, Julien Auguste Germain Boudet
-
Patent number: 10988763Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine (a non-complementary nucleotide) or a uridine in position opposite to the target adenosine to be edited in the target RNA region.Type: GrantFiled: June 22, 2017Date of Patent: April 27, 2021Assignee: PROQR THERAPEUTICS II B.V.Inventors: Janne Juha Turunen, Petra Geziena De Bruijn, Bart Klein, Roxana Simona Redis, Lenka Van Sint Fiet
-
Publication number: 20210079393Abstract: The invention relates to editing oligonucleotides (EONs) that carry 2?-0-methoxyethyl (2?-MOE) ribose modifications at specified positions and that do not carry such modifications on positions that would lower RNA editing efficiency. The selection of positions that should or should not carry a 2?-MOE modification is based on computational modelling that revealed steric clashes between the 2?-MOE modification and mammalian ADAR enzymes.Type: ApplicationFiled: February 11, 2019Publication date: March 18, 2021Inventors: Julien Auguste Germain Boudet, Lenka Van Sint Fiet, Janne Juha Turunen
-
Patent number: 10941402Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.Type: GrantFiled: August 31, 2017Date of Patent: March 9, 2021Assignee: PROQR THERAPEUTICS II B.V.Inventors: Janne Juha Turunen, Antti Aalto, Bart Klein, Lenka Van Sint Fiet, Julien Auguste Germain Boudet
-
Publication number: 20210010002Abstract: The invention relates to nucleic acid molecules for pseudouridylation of a target uridine in a target RNA in a mammalian cell, wherein the nucleic acid molecule comprises a guide region capable of forming a partially double stranded nucleic acid complex with the target RNA comprising the target uridine, wherein the partially double stranded nucleic acid complex is capable of engaging a mammalian pseudouridylation enzyme, wherein the guide region assists in positioning the target uridine in the partially double stranded nucleic acid complex for it to be converted to a pseudouridine by the mammalian pseudouridylation enzyme.Type: ApplicationFiled: March 27, 2019Publication date: January 14, 2021Inventors: Bart Klein, Janne Juha Turunen, Lenka Van Sint Fiet, Pedro Duarte Morais Fernandes Arantes Da Silva, Julien Auguste Germain Boudet, Yi-Tao Yu, Hironori Adachi, Meemanage De Zoysa
-
Publication number: 20190330622Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine (a non-complementary nucleotide) or a uridine in position opposite to the target adenosine to be edited in the target RNA region.Type: ApplicationFiled: June 22, 2017Publication date: October 31, 2019Inventors: Janne Juha Turunen, Petra Geziena De Bruijn, Bart Klein, Roxana Simona Redis, Lenka Van Sint Fiet
-
Publication number: 20190218552Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.Type: ApplicationFiled: August 31, 2017Publication date: July 18, 2019Inventors: Janne Juha Turunen, Antti Aalto, Bart Klein, Lenka Van Sint Fiet, Julien Auguste Germain Boudet